Literature DB >> 16724348

K-ras, p53 mutations, and microsatellite instability (MSI) in gallbladder cancer.

Angelica A Saetta1.   

Abstract

Despite the considerable progress in understanding the molecular pathology of carcinogenesis, the genetic mechanisms underlying the development and progression of gallbladder cancer (GC) are poorly understood. The survival of GC patients is generally poor. Therefore, it is very useful to define valuable prognostic factors. The most extensively studied oncogenes in gallbladder carcinogenesis are ras, commonly mutated in neoplasms of the gastrointestinal tract. K-ras oncogene is altered in a subset of gallbladder patients and mainly in those having anomalous junction of the pancreaticobiliary tract. Most of the studies of genetic abnormalities in GC have focused on p53 gene. p53 mutation/overexpression and/or LOH is present in more than 50% of gallbladder carcinomas, suggesting an important role in their pathogenesis. However, these results have not any predictive value yet. Moreover, the involvement of an alternative molecular pathway, that of microsatellite instability (MSI), is found in a limited group of GC patients. Additional research is necessary to establish its possible relation to defects of the mismatch repair (MMR) system and its proposed prognostic significance. Further elucidation of the molecular events specific to GC will help to identify novel molecular targets for the diagnosis and clinical management of the patients. Copyright 2006 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16724348     DOI: 10.1002/jso.20532

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  10 in total

Review 1.  Gallbladder cancer.

Authors:  Mislav Rakić; Leonardo Patrlj; Mario Kopljar; Robert Kliček; Marijan Kolovrat; Bozo Loncar; Zeljko Busic
Journal:  Hepatobiliary Surg Nutr       Date:  2014-10       Impact factor: 7.293

2.  Gallbladder cancer: the basics.

Authors:  Eldon A Shaffer
Journal:  Gastroenterol Hepatol (N Y)       Date:  2008-10

3.  Correlation of p53 gene mutation and expression of P53 protein in cholangiocarcinoma.

Authors:  Xiao-Fang Liu; Hao Zhang; Shi-Guang Zhu; Xian-Ting Zhou; Hai-Long Su; Zheng Xu; Shao-Jun Li
Journal:  World J Gastroenterol       Date:  2006-08-07       Impact factor: 5.742

4.  Microsatellite instability in gallbladder carcinoma.

Authors:  Andrea P Moy; Mohammad Shahid; Cristina R Ferrone; Darrell R Borger; Andrew X Zhu; David Ting; Vikram Deshpande
Journal:  Virchows Arch       Date:  2015-02-14       Impact factor: 4.064

5.  Genetic Analysis of Brazilian Patients with Gallbladder Cancer.

Authors:  Cristina Sábato; Luciana Bastos-Rodrigues; Debora Chaves Moraes; Eitan Friedman; Luiz De Marco; Vivian Resende
Journal:  Pathol Oncol Res       Date:  2018-03-19       Impact factor: 3.201

Review 6.  Pathology of gallbladder carcinoma: current understanding and new perspectives.

Authors:  Munita Meenu Bal; Mukta Ramadwar; Kedar Deodhar; Shailesh Shrikhande
Journal:  Pathol Oncol Res       Date:  2015-01-25       Impact factor: 3.201

7.  Geographic variation of gallbladder cancer mortality and risk factors in Chile: a population-based ecologic study.

Authors:  Marcelo E Andia; Ann W Hsing; Gabriella Andreotti; Catterina Ferreccio
Journal:  Int J Cancer       Date:  2008-09-15       Impact factor: 7.396

8.  miR-125b suppresses cellular proliferation by targeting c-FLIP in gallbladder carcinoma.

Authors:  Huajie Zong; Huading Zhou; Yang Xiang; Gang Wu
Journal:  Oncol Lett       Date:  2019-10-18       Impact factor: 2.967

Review 9.  Gallbladder cancer: epidemiology and outcome.

Authors:  Rajveer Hundal; Eldon A Shaffer
Journal:  Clin Epidemiol       Date:  2014-03-07       Impact factor: 4.790

Review 10.  Gallbladder cancer epidemiology, pathogenesis and molecular genetics: Recent update.

Authors:  Aarti Sharma; Kiran Lata Sharma; Annapurna Gupta; Alka Yadav; Ashok Kumar
Journal:  World J Gastroenterol       Date:  2017-06-14       Impact factor: 5.742

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.